BiotechTube

VXA-G1.1-NN

Phase 1Completed
2 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Norovirus Infections

Conditions

Norovirus Infections

Trial Timeline

Jan 24, 2022 → Feb 24, 2022

NCT ID
NCT05213728

About VXA-G1.1-NN

VXA-G1.1-NN is a phase 1 stage product being developed by Vaxart for Norovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT05213728. Target conditions include Norovirus Infections.

What happened to similar drugs?

0 of 1 similar drugs in Norovirus Infections were approved

Approved (0) Terminated (0) Active (1)
🔄mRNA-1403ModernaPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05213728Phase 1Completed
NCT04875676Phase 1/2Completed

Competing Products

13 competing products in Norovirus Infections

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
VXA-G1.1-NN + VXA-G2.4-NS + Placebo TabletsVaxartPhase 1
19
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine TabletVaxartPhase 1
19
VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-TVaxartPhase 1
23
VXA-G1.1-NNVaxartPhase 1/2
22
VXA-G1.1-NN Oral VaccineVaxartPhase 1
19
Norwalk GI.1 VirusVaxartPhase 1
19
VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus InoculumVaxartPhase 1/2
22
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + PlaceboVaxartPhase 2
25
VXA-G1.1-NN + VXA-G2.4-NS + Placebo TabletsVaxartPhase 1
19
VXA-GI.1.NN + Placebo TabletVaxartPhase 1
19
CDI-988 + PlaceboCocrystal PharmaPhase 1/2
29